002793 Stock Overview
Luoxin Pharmaceuticals Group Stock Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Luoxin Pharmaceuticals Group Stock Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.17 |
| 52 Week High | CN¥5.80 |
| 52 Week Low | CN¥3.22 |
| Beta | 0.51 |
| 1 Month Change | -6.50% |
| 3 Month Change | -6.29% |
| 1 Year Change | -19.96% |
| 3 Year Change | -60.25% |
| 5 Year Change | -69.29% |
| Change since IPO | -71.06% |
Recent News & Updates
Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Held Back By Insufficient Growth Even After Shares Climb 41%
Oct 21
Why Investors Shouldn't Be Surprised By Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Low P/S
Aug 23Luoxin Pharmaceuticals Group Stock (SZSE:002793) Is Making Moderate Use Of Debt
Jun 25Recent updates
Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Held Back By Insufficient Growth Even After Shares Climb 41%
Oct 21Why Investors Shouldn't Be Surprised By Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Low P/S
Aug 23Luoxin Pharmaceuticals Group Stock (SZSE:002793) Is Making Moderate Use Of Debt
Jun 25Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price Is Right But Growth Is Lacking After Shares Rocket 25%
May 21Subdued Growth No Barrier To Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price
Feb 28Shareholder Returns
| 002793 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.2% | -5.0% | -7.1% |
| 1Y | -20.0% | -8.2% | 3.9% |
Return vs Industry: 002793 underperformed the CN Pharmaceuticals industry which returned -8.2% over the past year.
Return vs Market: 002793 underperformed the CN Market which returned 3.9% over the past year.
Price Volatility
| 002793 volatility | |
|---|---|
| 002793 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002793 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002793's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 3,388 | Zhenteng Liu | www.luoxin.cn |
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Fundamentals Summary
| 002793 fundamental statistics | |
|---|---|
| Market cap | CN¥4.43b |
| Earnings (TTM) | -CN¥697.00m |
| Revenue (TTM) | CN¥2.42b |
1.8x
P/S Ratio-6.4x
P/E RatioIs 002793 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002793 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.42b |
| Cost of Revenue | CN¥1.45b |
| Gross Profit | CN¥967.61m |
| Other Expenses | CN¥1.66b |
| Earnings | -CN¥697.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 40.01% |
| Net Profit Margin | -28.82% |
| Debt/Equity Ratio | 86.0% |
How did 002793 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:16 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Luoxin Pharmaceuticals Group Stock Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jayaprabha Dhavale | Virtua Research Inc. |